目的 探討阿托伐他汀對(duì)慢性心衰患者NT-proBNP水平及氧化應(yīng)激狀態(tài)的影響。方法 選擇2015年9月—2017年2月非缺血性心臟病慢性心衰患者102例，將所有患者隨機(jī)分為對(duì)照組（n=51）和阿托伐他汀組（n=51）。對(duì)照組實(shí)施常規(guī)抗心衰藥物治療，阿托伐他汀組在常規(guī)抗心衰治療基礎(chǔ)上加用阿托伐他汀治療，20 mg/d。兩組療程均為24周。觀察并比較兩組治療前后三酰甘油（TG）、總膽固醇（TC）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）、NYHA分級(jí)、左室射血分?jǐn)?shù)（LVEF）、NT-proBNP、6 min步行距離（6MWT）、超氧化物歧化酶（SOD）、髓過氧化物酶（MPO）、丙二醛（MDA）等指標(biāo)。結(jié)果 阿托伐他汀組治療后TG、TC、LDL-C水平明顯下降，與治療前及對(duì)照組比較，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者治療后NT-proBNP水平均有明顯下降，與治療前比較，差異有統(tǒng)計(jì)學(xué)意義（P<0.05），但阿托伐他汀組下降幅度優(yōu)于對(duì)照組，組間比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。與同組治療前及對(duì)照組比較，阿托伐他汀組治療后SOD明顯增高，MDA、MPO明顯下降，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）；而對(duì)照組治療前后無明顯變化。結(jié)論 在常規(guī)抗心衰治療的基礎(chǔ)上加用阿托伐他汀，能有效降低CHF患者的NT-proBNP水平和抑制患者的氧化應(yīng)激狀態(tài)。

Objective To explore the influence of atorvastatin on N-terminal brain natriuretic peptide (NT-proBNP) and oxidative stress in patients with chronic heart failure (CHF). Methods 102 cases of chronic heart failure patients with non-ischaemic heart disease were chosen as chosen as the research objects. The patients were randomly divided into control group (n=51) and atorvastatin group (n=51). The patients were treated with the conventional drugs in control group, and combined with atorvastatin of 20 mg/d in atorvastatin group. All patients were treated for 12 weeks. Triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), low density lipoprotein (LDL-C), NYHA classification, left ventricular ejection fraction (LVEF), NT-proBNP, 6 min walking distance (6 MWT), SOD, MPO, MDA were observed and compared before and after treatment in two groups. Results Compared with before treatment and control group, TG, TC, LDL-C decreased obviously after treatment in atorvastatin group, the differences were statistically significant (P < 0.05). NT-proBNP levels decreased significantly after treatment in two groups, compared with that before treatment, the differences were statistically significant (P < 0.05), but the change in atorvastatin group was better than that in control group (P < 0.05). Compared with those before treatment and control group, SOD increased significantly, MDA, MPO decreased significantly after treatment in atorvastatin group, the differences were statistically significant (P < 0.05). The control group had no significant change before and after treatment. Conclusion The conventional anti-heart failure treatment added with atorvastatin could reduce effectively NT-proBNP level and inhibit oxidative stress in CHF patients.